Public Employees Retirement System of Ohio Has $4.48 Million Holdings in United Therapeutics Corporation $UTHR

Public Employees Retirement System of Ohio raised its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 0.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,580 shares of the biotechnology company’s stock after buying an additional 103 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in United Therapeutics were worth $4,477,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in UTHR. Two Sigma Investments LP grew its holdings in United Therapeutics by 3.0% in the 4th quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company’s stock valued at $626,000 after buying an additional 52 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of United Therapeutics by 15.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,643 shares of the biotechnology company’s stock worth $1,991,000 after acquiring an additional 769 shares during the period. GAMMA Investing LLC lifted its position in shares of United Therapeutics by 29,415.2% in the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock worth $68,422,000 after acquiring an additional 221,202 shares during the period. Unigestion Holding SA bought a new stake in shares of United Therapeutics in the 1st quarter worth approximately $2,672,000. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of United Therapeutics by 84.7% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 4,297 shares of the biotechnology company’s stock worth $1,325,000 after acquiring an additional 1,970 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In related news, Director Christopher Causey sold 1,000 shares of United Therapeutics stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $440.00, for a total transaction of $440,000.00. Following the completion of the sale, the director directly owned 4,865 shares of the company’s stock, valued at $2,140,600. The trade was a 17.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Judy D. Olian sold 1,800 shares of United Therapeutics stock in a transaction on Friday, September 19th. The stock was sold at an average price of $415.43, for a total value of $747,774.00. Following the sale, the director directly owned 5,045 shares of the company’s stock, valued at approximately $2,095,844.35. This trade represents a 26.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 196,935 shares of company stock valued at $75,618,342 over the last quarter. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $424.31 on Tuesday. The stock has a fifty day moving average of $345.52 and a 200-day moving average of $315.67. The stock has a market capitalization of $19.14 billion, a P/E ratio of 16.56, a price-to-earnings-growth ratio of 6.60 and a beta of 0.62. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $442.01.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period last year, the business posted $5.85 earnings per share. The firm’s quarterly revenue was up 11.7% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on UTHR shares. Bank of America raised their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Royal Bank Of Canada started coverage on United Therapeutics in a research report on Friday. They issued an “outperform” rating and a $569.00 price objective for the company. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, HC Wainwright raised their price objective on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Ten investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $449.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.